NCT01412450已完成4 期
DURABILITY-POP Study - Physician Initiated Trial Investigating the Efficacy of the Implant of Protégé EverFlex Nitinol Stents in Popliteal Lesions
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 4
- 主要终点
- primary patency
研究概览
简要总结
This study will assess the results up to 12 months with the Protégé EverFlex stent (ev3) in patients presenting with a narrowing or blocking at the level of the knee artery, which leads to a limited walking distance, rest pain or non-healing ulcers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion criteria
- •De novo, restenotic or reoccluded lesion located in the popliteal artery, with or without superficial femoral artery involvement
- •Patient presenting a score from 2 to 5 following Rutherford classification
- •Patient is willing to comply with specified follow-up evaluations at the specified times
- •Patient is >18 years old
- •Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- •Prior to enrollment, the guidewire has crossed target lesion
- •Patient is eligible for treatment with the self-expanding nitinol EverFlex (ev3) stent
- •Angiographic Inclusion Criteria
- •The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation
- •The target lesion, visually estimated, has a maximal length of 14 cm and can be categorized as either a type A or B lesions according the TASC II guidelines
- •Target vessel diameter visually estimated is >3.5mm and <7.5 mm
- •There is angiographic evidence of at least one-vessel-runoff to the foot
排除标准
- •Presence of another stent in the target vessel that was placed during a previous procedure
- •Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
- •Previous by-pass surgery in the same limb
- •Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
- •Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
- •Perforation at the angioplasty site evidenced by extravasation of contrast medium
- •Patients with known hypersensitivity to nickel-titanium
- •Patients with uncorrected bleeding disorders
- •Aneurysm located at the level of the SFA and/or popliteal artery
- •Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
- •Life expectancy of less than twelve months
- •Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis > 30% or ipsilateral iliac treatment conducted after the target lesion procedure
- •Use of thrombectomy, artherectomy or laser devices during procedure
- •Any patient considered to be hemodynamically unstable at onset of procedure
- •Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period.
研究组 & 干预措施
nitinol stent
Experimental
Protégé EverFlex stent
干预措施: nitinol stent (Device)
结局指标
主要结局
primary patency
时间窗: 12 months post-procedure
primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) and without TLR within 12 months
次要结局
- Technical success(1 day post-procedure)
- Primary patency rate at 6-, 12-month follow-up.(6-, 12-month follow-up)
- Clinical success(6-, 12-month follow-up)
- tent fracture rate at 12-month follow-up(12-month follow-up)
- Serious adverse events(1 year)
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
不适用
EASYII - E-tegra Stent Graft System - Imaging CohortVascular AneurysmNCT05586503JOTEC GmbH25
已完成
不适用
EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical StudyPeripheral Arterial DiseasesNCT02066740Medtronic Endovascular34
已完成
不适用
In Stent ELUTES StudyCoronary Artery DiseaseNCT00225680Cook Group Incorporated124
已完成
不适用
Neopep-S-based EasyDew MD Regen Cream for Radiotherapy Subject After Breast Tumor ResectionSkin LesionNCT06025058Eun-ji Kim30
已完成
不适用
Extension Study of Original Protocol AERO C009 for Obstructive Sleep Apnea-hypopneaOSAHObstructive Sleep Apnea HypopneaObstructive Sleep ApneaNCT00849043Ventus Medical, Inc.65